Business Wire

Maina Bhaman Joins Sofinnova Partners as Partner

Jaa

Sofinnova Partners, a leading Life Sciences venture capital firm focused on Europe, has appointed Maina Bhaman as Partner.

Maina Bhaman comes to Sofinnova Partners with a long track record as a successful healthcare investor. Prior to joining, she was Director of Healthcare Investment at Touchstone Innovations (formerly Imperial Innovations) in London (UK) since 2006. She has led or co-led numerous investments and sat on the Board of a number of UK biotech companies, such as Autifony, Cellmedica, Psioxus Therapeutics, Pulmocide, Topivert Pharma, Puridify (sold to GE), Thiakis (sold to Wyeth) and Respivert (sold to J&J). Previously, she worked in the R&D teams of several UK and US biotech companies, including Celltech, Oxford Glyco Sciences, Chimeric Therapies and GeneMedicine. Maina has a BSc from the University of Texas at Austin (United States) and an MBA from the Imperial Business School in London (United Kingdom).

As a long standing member of the biotech ecosystem, Maina has received strong professional and institutional recognition; and was named one of UK’s Top women in Biopharma several years in a row. With Maina Bhaman’s arrival, Sofinnova Partners continues to build a truly international team with a unique diversity.

Maina Bhaman says: “I am thrilled to join such an experienced team as Sofinnova Partners. We have worked together on a number of co-investments, and clearly share a common approach and vision. I am looking forward to continue to pursue my passion of backing entrepreneurs developing paradigm-shifting technologies that may significantly improve patients’ life”.

Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, adds: “We are extremely happy to welcome Maina as a Partner in our team. Her expertise and track record are a perfect match with our team and strategy. This recruitment also furthers our international reach and will positively contribute to Sofinnova Partners’ growth”.

Contact information

Media
SOFINNOVA PARTNERS
Anne REIN, Tel: +33 6 03 35 92 05
@: anne.rein@strategiesimage.com
www.sofinnova.fr

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

STATS Unveils STATS GPS, the Most Advanced Technology for Athlete Monitoring21.5.2018 10:00Tiedote

Today, STATS, the worldwide leader in sports data and intelligence, unveiled STATS GPS, an innovative system that uses a revolutionary 50-Hz sampling frequency to provide the most advanced real-time GPS technology available. STATS GPS allows teams to monitor player performance with customizable metrics like accelerations/decelerations, energy expenditure, count of zone entries, and time, distance and power thresholds. The innovative solution uses real 50-Hz sampling frequency and allows practitioners to monitor up to 100 players in real-time and post session with over 300 GPS, IMU and HR derived metrics. Embedded in the GPS vests are textile heart-rate sensors, making STATS GPS the most advanced technology on the market. “Teams and conditioning coaches need the latest technology to ensure players stay at peak health and fitness during long seasons,” said Ryan Paterson, Chief Global Officer at STATS. “With STATS GPS’ new 50-Hz technology, teams can instantly get performance information,

Sofinnova Partners Appoints Dr. Martin T. Rothman as Venture Partner21.5.2018 09:00Tiedote

Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, has appointed Dr. Martin T. Rothman as Venture Partner. Dr. Rothman brings forty years of experience and a strong international network in the medical field to Sofinnova Partners. As Venture Partner, Dr. Rothman will focus on helping the team identify and evaluate promising medical device companies and on mentoring entrepreneurs and physicians launching clinical innovations. Sofinnova Partners and Dr. Rothman have closely collaborated over many years. Dr. Rothman is the founder of LimFlow and an independent board member of HighLife, both portfolio companies of Sofinnova Partners. Until recently, he was Vice President of medical affairs for coronary, structural heart and renal denervation for Medtronic, based in Santa Rosa (CA), a position he held since 2010. He was involved in the development of the renal denervation program, the Trans-Aortic Valve Replacement program, and the Medtronic percutaneo

MATCHESFASHION.COM Has Another Strong Year of Growth Driven by International Expansion21.5.2018 09:00Tiedote

MATCHESFASHION.COM, the global luxury-shopping destination for men and women, experienced another strong year of growth in 2017 with revenue up 44% year on year. EBITDA was up 34% driven by international growth. Technology has enabled the business to scale internationally, enhance the customer experience and power social innovation such as the launch of The Style Daily and The Style Social, delivering unique daily content to users. The success of the app last year led to more than half of online business being conducted via mobile. 2017 also saw the launch of two local-language websites in French and Korean and, in October, funds advised by Apax Partners acquired a majority stake in the company. Building on this momentum in 2018, MATCHESFASHION.COM increased their physical footprint; the Hong Kong office has tripled in size and in April they launched a state-of-the-art creative studio in East London. In the summer a new 500,000 square ft global distribution centre will open in London f

ResMed-sponsored Studies Show Combining Home Oxygen and Home Non-invasive Ventilation is a Cost Effective Treatment for COPD21.5.2018 00:15Tiedote

ResMed (NYSE: RMD, ASX: RMD) announced today the results of two clinical analyses conducted for the U.K. and U.S., demonstrating the cost effectiveness of combining home oxygen therapy and home non-invasive ventilation (NIV) therapy for patients with persistent hypercapnia following a life-threatening exacerbation of chronic obstructive pulmonary disease (COPD). The ResMed-backed Home Oxygen Therapy – Home Mechanical Ventilation (HOT-HMV) health economic studies, presented today at the ATS 2018 International Conference, build on earlier data demonstrating the clinical and cost effectiveness of HOT-HMV therapy (i.e. combining home oxygen therapy with home NIV), compared to treating with oxygen alone. The U.K. study found that HOT-HMV treatment reduced exacerbation frequency and 28-day hospital readmission. The U.S. analysis found a 58.3 percent reduction in 30-day readmissions for HOT-HMV patients compared to those on home oxygen alone – and that HOT-HMV can actually save patients money

WELL Building Standard Gaining Momentum in Europe18.5.2018 17:47Tiedote

As Greenbuild Europe came to a close in Berlin, the International WELL Building Institute™ (IWBI™) used the occasion to highlight how the WELL Building Standard™ (WELL™) has elevated health and well-being to the forefront of sustainability conversations across Europe. WELL continues to advance the healthy building movement as the premier standard for buildings, interior spaces and communities seeking to implement, validate and measure features that promote human health and wellness. The resonance of the program has spurred innovations across the building, design and construction industries, providing projects with customizable approaches to address geographical and cultural health concerns. To date, WELL has enrolled more than 830 projects encompassing over 155 million square feet of real estate in 32 countries worldwide. In Europe nearly 190 projects across 13 countries are engaged with WELL, representing 25% of global WELL project square footage. The strong growth of WELL over the pa

Utimaco Announces Intent to Acquire Atalla from Micro Focus18.5.2018 12:03Tiedote

Utimaco, the global #2 in Hardware Security Modules (HSMs), today announced the intent to acquire the Atalla HSM and ESKM business lines from Micro Focus, which were previously owned by Hewlett Packard Enterprise (HPE) prior to the September 2017 merger of its Software business with Micro Focus. Germany-based Utimaco, active in the HSM market for over 35 years, is a global manufacturer of general purpose HSMs. Utimaco has built its market leading position focusing on indirect sales through OEM or channel business partners and selling its SecurityServer product line into industries as diverse as automotive, government, media & entertainment, smart metering, semiconductors, telecommunications and the banking and financial services sectors. Utimaco is traditionally strong in its German home market based on its longstanding German banking association certification (DK) and has recently achieved PCI accreditation for the SecurityServer product line. With the acquisition of Atalla, one of th

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme